Archives of Gynecology and Obstetrics

, Volume 295, Issue 3, pp 689–696 | Cite as

Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: a systematic review and meta-analysis

  • Honglei Jia
  • Qingyu Zhang
  • Fanxiao Liu
  • Dongsheng Zhou
Gynecologic Oncology



The reported roles of matrix metalloproteinase 2 (MMP-2) on the prognosis of patients with epithelial ovarian cancers (EOCs) are inconsistent.


This meta-analysis was performed to evaluate the prognostic significance of MMP-2 for patients with EOCs by analyzing 11 studies.


We systematically searched articles in the Cochrane Library, Pubmed, Embase, China National Knowledge Infrastructure (CNKI), Wanfang Database, and Chinese Biological Medical (CBM) Database, updated to February 1st 2015, with the following search terms: ovarian neoplasm OR ovarian tumor OR ovarian carcinoma OR ovarian malignance OR ovarian cancer AND matrix metalloproteinase-2 OR MMP-2.


A total of 11 studies involving 1058 patients with EOCs were in accordance with the inclusion criteria. The pooled HR was 1.09 (95% CI 0.32–1.86, p = 0.006) in patients with overexpression of stromal MMP-2 with significant heterogeneity (I 2 = 53.1%, p = 0.074) between studies. For patients with MMP-2 overexpression in tumor cells, the pooled HR was 1.42 (95% CI 1.14–1.70, p = 0.000) with no significant heterogeneity (I 2 = 43.4%, p = 0.078) between studies. Sensitivity analyses were stable.


MMP-2 overexpression in tumor cells rather than stroma was significantly associated with poor prognosis in patient with endothelial ovarian cancer; however, the result remains to be confirmed with additional high-quality studies.


Meta-analysis MMP-2 Ovarian epithelial carcinoma Prognostic value 



The study was supported by the National Natural Science Foundation of China (No. 81301556).

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of Shandong Provincial Hospital Affiliated to Shandong University and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    American Cancer Society (2015) Cancer facts and figures 2015. American Cancer Society, AtlantaGoogle Scholar
  2. 2.
    Sun C, Li N, Ding D et al (2014) The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis. PLoS One 9:95285CrossRefGoogle Scholar
  3. 3.
    Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108CrossRefPubMedGoogle Scholar
  4. 4.
    Liu R, Lu S, Deng Y et al (2016) PSMB4 expression associates with epithelial ovarian cancer growth and poor prognosis. Arch Gynecol Obstet 293(6):1297–1307CrossRefPubMedGoogle Scholar
  5. 5.
    Perigny M, Bairati I, Harvey I et al (2008) Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol 129:226–231CrossRefPubMedGoogle Scholar
  6. 6.
    Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54:1046–1055CrossRefPubMedGoogle Scholar
  7. 7.
    Pan Y, Zhu D, Si WN et al (2008) Expressions of RhoC and MMP-2 proteins in epithelial ovarian cancer tissues and their clinical significances. J Jilin Univ Medicine Edition) 34:1042–1045Google Scholar
  8. 8.
    Kucukgoz GU, Gumurdulu D, Guzel AB et al (2014) Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma. Arch Gynecol Obstet 289(2):393–398CrossRefGoogle Scholar
  9. 9.
    Peng H, Liu L, Zhao X (2013) Prognostic significance of matrix metalloproteinase-2 in gynecological cancer: a systemic review of the literature and meta-analysis. J BUON 18:202–210PubMedGoogle Scholar
  10. 10.
    Horner MJ, Ries LAG, Krapcho M et al (2009) SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. In: Bethesda, MD (ed) SEER Cancer Statistics ReviewGoogle Scholar
  11. 11.
    Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Yu L, Wang WY, Gan HY et al (2011) Expression and clinical significance of MMP-2 and MMP-7 in ovarian carcinoma. Chinese J Histochem Cytochem 20:325–329Google Scholar
  13. 13.
    Huang KJ, Sui LH (2012) The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. Med Oncol 29:318–323CrossRefPubMedGoogle Scholar
  14. 14.
    Liu J, Ping W, Zu Y et al (2014) Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer. Int J Clin Exp Pathol 7:6040–6047PubMedPubMedCentralGoogle Scholar
  15. 15.
    Ekinci T, Ozbay PO, Yiğit S et al (2014) The correlation between immunohistochemical expression of MMP-2 and the prognosis of epithelial ovarian cancer. Ginekol Pol 85:121–130CrossRefPubMedGoogle Scholar
  16. 16.
    Lynch CC (2011) Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis. Bone 48:44–53CrossRefPubMedGoogle Scholar
  17. 17.
    Wen X, Liu H, Yu K et al (2014) Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis. Tumour Biol 35:845–848CrossRefPubMedGoogle Scholar
  18. 18.
    Su Z, Graybill WS, Zhu Y (2013) Detection and monitoring of ovarian cancer. Clin Chim Acta 415:341–345CrossRefPubMedGoogle Scholar
  19. 19.
    Wu DB, Yang J, Yao YL et al (2013) Expression and clinical significance of MMP-2 and MMP-7 in ovarian carcinoma. Proceed Clin Med 22:650–652Google Scholar
  20. 20.
    Wells G, Shea B, Peterson J et al (2000) The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 3rd symposium on systematic reviews: beyond the basics. pp 3–5Google Scholar
  21. 21.
    Gentry-Maharaj A, Menon U (2012) Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol 26:243–256CrossRefPubMedGoogle Scholar
  22. 22.
    Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834CrossRefPubMedGoogle Scholar
  24. 24.
    Wang XY, Zhang YK, Ren GH (2004) Relation between expression of MMP-2 and MMP-9 and invasion, metastasis of epithelial carcinoma of ovary. Chin J Oncol Rahabil 11:406–408Google Scholar
  25. 25.
    Westerlund A, Apaja-Sarkkinen M, Höyhtyä M et al (1999) Gelatinase A-immunoreactive protein in ovarian lesions- prognostic value in epithelial ovarian cancer. Gynecol Oncol 75:91–98CrossRefPubMedGoogle Scholar
  26. 26.
    Torng PL, Mao TL, Chan WY et al (2004) Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol Oncol 92:559–567CrossRefPubMedGoogle Scholar
  27. 27.
    Kamat AA, Fletcher M, Gruman LM et al (2006) The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 12:1707–1714CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Sillanpaa S, Anttila M, Suhonen K et al (2007) Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol 28:280–289CrossRefPubMedGoogle Scholar
  29. 29.
    Wu X, Li H, Kang L et al (2002) Activated matrix metalloproteinase-2–a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol 84:126–134CrossRefPubMedGoogle Scholar
  30. 30.
    Davidson B, Reich R, Berner A et al (2001) Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer 37:2040–2049CrossRefPubMedGoogle Scholar
  31. 31.
    Chen VW, Bernardo R, Jeffrey L et al (2003) Pathology and classification of ovarian tumors. Cancer 97(10 Suppl):2631–2642CrossRefPubMedGoogle Scholar
  32. 32.
    Yu WH, Woessner JF Jr, McNeish JD et al (2002) CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16:307–323CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Campo E, Merino MJ, Tavassoli FA et al (1992) Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 16:500–507CrossRefPubMedGoogle Scholar
  34. 34.
    Lydiksen L, Jensen-Fangel S, Blaakaer J (2014) Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer? Gynecol Oncol 133:454–459CrossRefPubMedGoogle Scholar
  35. 35.
    Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52–67CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Honglei Jia
    • 1
  • Qingyu Zhang
    • 2
  • Fanxiao Liu
    • 1
  • Dongsheng Zhou
    • 1
  1. 1.Shandong Provincial Hospital Affiliated to Shandong UniversityJinanChina
  2. 2.Qilu Hospital Affiliated to Shandong UniversityJinanChina

Personalised recommendations